COMPASS PATHWAYS PLC Research and Development Expense
COMPASS PATHWAYS PLC (CMPS) reported Research and Development Expense of $29.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- COMPASS PATHWAYS PLC research and development expense for the quarter ending 2026-06-30 was $29.18M, a 3.79% decline year-over-year.
- COMPASS PATHWAYS PLC research and development expense for the quarter ending 2026-03-31 was $26.48M, a 14.25% decline year-over-year.
- COMPASS PATHWAYS PLC research and development expense for the quarter ending 2025-12-31 was $29.91M, a 6.95% decline year-over-year.
- COMPASS PATHWAYS PLC research and development expense for the quarter ending 2025-09-30 was $27.32M, a 17.02% decline year-over-year.
- COMPASS PATHWAYS PLC research and development expense for fiscal 2025 was $118.44M, a 0.51% decline from fiscal 2024.
- COMPASS PATHWAYS PLC research and development expense for fiscal 2024 was $119.04M, a 36.02% increase from fiscal 2023.
- COMPASS PATHWAYS PLC research and development expense for fiscal 2023 was $87.52M, a 34.53% increase from fiscal 2022.
- COMPASS PATHWAYS PLC research and development expense for fiscal 2022 was $65.05M, a 47.76% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.18M 10-Q · filed 2026-08-05 | $55.66M 10-Q · filed 2026-08-05 | $85.56M derived: sum of 3 quarters · filed 2026-08-05 | $112.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $26.48M 10-Q · filed 2026-05-13 | $56.39M derived: sum of 2 quarters · filed 2026-05-13 | $83.71M derived: sum of 3 quarters · filed 2026-05-13 | $114.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $29.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $57.23M derived: sum of 2 quarters · filed 2026-03-24 | $87.56M derived: sum of 3 quarters · filed 2026-08-05 | $118.44M 10-K · filed 2026-03-24 |
| 2025-09-30 | $27.32M 10-Q · filed 2025-11-04 | $57.65M derived: sum of 2 quarters · filed 2026-08-05 | $88.53M 10-Q · filed 2025-11-04 | $120.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $30.32M 10-Q · filed 2026-08-05 | $61.20M 10-Q · filed 2026-08-05 | $93.35M derived: sum of 3 quarters · filed 2026-08-05 | $126.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $30.88M 10-Q · filed 2026-05-13 | $63.02M derived: sum of 2 quarters · filed 2026-05-13 | $95.95M derived: sum of 3 quarters · filed 2026-05-13 | $125.02M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $32.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $65.07M derived: sum of 2 quarters · filed 2026-03-24 | $94.14M derived: sum of 3 quarters · filed 2026-03-24 | $119.04M 10-K · filed 2026-03-24 |
| 2024-09-30 | $32.93M 10-Q · filed 2025-11-04 | $62.00M derived: sum of 2 quarters · filed 2025-11-04 | $86.90M 10-Q · filed 2025-11-04 | $114.04M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $29.07M 10-Q · filed 2025-07-31 | $53.97M 10-Q · filed 2025-07-31 | $81.11M derived: sum of 3 quarters · filed 2025-07-31 | $102.64M derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | $24.90M 10-Q · filed 2025-05-08 | $52.04M derived: sum of 2 quarters · filed 2025-05-08 | $73.57M derived: sum of 3 quarters · filed 2025-05-08 | $93.38M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $27.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $48.66M derived: sum of 2 quarters · filed 2025-02-27 | $68.48M derived: sum of 3 quarters · filed 2025-02-27 | $87.52M 10-K · filed 2025-02-27 |
| 2023-09-30 | $21.53M 10-Q · filed 2024-10-31 | $41.34M derived: sum of 2 quarters · filed 2024-10-31 | $60.38M 10-Q · filed 2024-10-31 | $80.17M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $19.82M 10-Q · filed 2024-08-01 | $38.85M 10-Q · filed 2024-08-01 | $58.65M derived: sum of 3 quarters · filed 2024-08-01 | $72.62M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $19.04M 10-Q · filed 2024-05-08 | $38.83M derived: sum of 2 quarters · filed 2024-05-08 | $52.81M derived: sum of 3 quarters · filed 2024-05-08 | $68.73M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $19.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $33.77M derived: sum of 2 quarters · filed 2024-02-29 | $49.69M derived: sum of 3 quarters · filed 2024-02-29 | $65.05M 10-K · filed 2024-02-29 |
| 2022-09-30 | $13.98M 10-Q · filed 2023-11-02 | $29.90M derived: sum of 2 quarters · filed 2023-11-02 | $45.26M 10-Q · filed 2023-11-02 | $58.85M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $15.92M 10-Q · filed 2023-08-03 | $31.28M 10-Q · filed 2023-08-03 | $44.88M derived: sum of 3 quarters · filed 2024-02-29 | $57.07M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $15.36M 10-Q · filed 2023-05-11 | $28.95M derived: sum of 2 quarters · filed 2024-02-29 | $41.15M derived: sum of 3 quarters · filed 2024-02-29 | $52.51M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $13.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $25.79M derived: sum of 2 quarters · filed 2024-02-29 | $37.14M derived: sum of 3 quarters · filed 2024-02-29 | $44.03M 10-K · filed 2024-02-29 |
| 2021-09-30 | $12.20M 10-Q · filed 2022-11-03 | $23.55M derived: sum of 2 quarters · filed 2022-11-03 | $30.43M 10-Q · filed 2022-11-03 | $34.98M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $11.35M 10-Q · filed 2022-08-04 | $18.24M 10-Q · filed 2022-08-04 | $22.78M derived: sum of 3 quarters · filed 2023-02-28 | $29.66M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $6.88M 10-Q · filed 2022-05-10 | $11.43M derived: sum of 2 quarters · filed 2023-02-28 | $18.30M derived: sum of 3 quarters · filed 2023-02-28 | $25.03M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $4.54M derived: 10-K 12 month − 6-K 9 month · filed 2023-02-28 | $11.42M derived: sum of 2 quarters · filed 2023-02-28 | $18.14M derived: sum of 3 quarters · filed 2023-02-28 | $23.37M 10-K · filed 2023-02-28 |
| 2020-09-30 | $6.88M 6-K · filed 2021-11-09 | $13.60M derived: sum of 2 quarters · filed 2021-11-09 | $18.82M 6-K · filed 2021-11-09 | |
| 2020-06-30 | $6.72M 6-K · filed 2021-08-11 | $11.95M 6-K · filed 2021-08-11 | ||
| 2019-12-31 | $12.56M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |